Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 13, 2009 Brian Orelli	WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year.
The Motley Fool October 1, 2008 Brian Orelli	WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap.
The Motley Fool October 31, 2005 Brian Gorman	Charles River Labs' Seesaw The company is balancing softness in its research models with strength in preclinical services. A wait-and-see attitude toward the stock may be appropriate due to weakness in research models and the company's ambitious expansion plans.
The Motley Fool May 4, 2005 Brian Gorman	Relaxing on the River Charles River Laboratories' full suite of services looks like a winning concept.
The Motley Fool May 10, 2006 Brian Gorman	Charles River Restructures For the near term, restructuring plans should keep this one in limbo. Investors shouldn't expect too much from the company right now.
The Motley Fool February 9, 2006 Brian Gorman	Charles River Bets on Preclinical The company is reportedly seeing more activity from biotech outfits, in addition to existing business from larger pharmaceutical names like Eli Lilly and Pfizer. But a large expansion in preclinical capacity warrants close watching. Investors, take note.
The Motley Fool August 9, 2006 Brian Gorman	Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note.
The Motley Fool July 1, 2004 Brian Gorman	Charles River's Big Buy Charles River Laboratories is buying Inveresk Research Group in what appears to be a bid to control more of the burgeoning market for preclinical drug development services.
The Motley Fool November 7, 2006 Brian Gorman	Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note.
The Motley Fool August 1, 2008 Brian Orelli	Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit.
The Motley Fool June 25, 2008 Brian Orelli	WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play?
The Motley Fool June 15, 2006 Brian Gorman	Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note.
The Motley Fool January 27, 2005 Brian Gorman	Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results.
The Motley Fool July 30, 2009 Robert Steyer	Covance Advances Covance latest results produce more optimism than did some of its contract research peers.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool April 24, 2009 Robert Steyer	Nothing to CRO About The good times have stopped rolling for Contract research organizations, as they warn of unexpected contract cancellations and reduced demand for services.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool October 1, 2004 Tom Taulli	Charles River, Outsourced Expert The legal/regulatory and business consulting firm upped its full-year fiscal 2004 guidance, with revenue growth at 30% to 35%. It is good to know the company takes its own advice it gives to clients.
The Motley Fool May 30, 2008 Brian Orelli	WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside.
The Motley Fool October 30, 2009 Brian Orelli	It's Not As Frightening As It First Appears Dig a little, and you'll see that generic-drug maker Mylan is far from a copycat of its struggling branded-drug-making counterparts.
The Motley Fool October 23, 2009 Robert Steyer	Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends.
The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool March 14, 2008 Brian Orelli	No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company.
The Motley Fool September 8, 2004 Charly Travers	Will a Clinical Trial Database Help Investors? While this development is certainly good news for patients and physicians, the impact on investors may be minimal, depending upon the type of data that will be released.
The Motley Fool April 28, 2006 Brian Gorman	Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note.
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
The Motley Fool August 25, 2006 Brian Gorman	California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely.
The Motley Fool August 4, 2004 Charly Travers	Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.
The Motley Fool October 9, 2006 Brian Lawler	New Drug for New River An approvable letter from the FDA sends shares of New River Pharmaceuticals up.
The Motley Fool July 31, 2009 Brian Orelli	Two Pictures of a Drug Company Who should we believe? The FDA? Mylan's earnings report?
The Motley Fool February 22, 2011 Ryan McBride	Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs.
The Motley Fool May 17, 2007 Rich Duprey	Foolish Forecast: My, Oh, Mylan The generic drug maker is set to report fourth-quarter 2007 financial results: Investors face the prospect of shareholder dilution, a cut in its credit rating, and the suspension of its dividend.
The Motley Fool January 27, 2006 Brian Gorman	Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet.
The Motley Fool January 29, 2009	Today's 5-Star Movers Today's list of top-moving stocks from the Motley Fool five-star stock list.
The Motley Fool October 5, 2004 W.D. Crotty	Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth.
The Motley Fool October 29, 2009 Robert Steyer	Pharma Researchers Need a Cure As the industry changes, Pharmaceutical Product Development and Parexel International struggle.
The Motley Fool August 20, 2004 Ben McClure	Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders.
The Motley Fool January 16, 2009 Brian Orelli	Lilly Pays Up. Big Deal. Lawsuits are just a fact of life when investing in drug companies, and pharmaceutical investors have to expect these kinds of legal defeats.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool May 13, 2008 Brian Orelli	Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company.
The Motley Fool July 27, 2009 Brian Orelli	Mylan Ruins It for Everyone If customers begin to mistrust generic drugs from Mylan or whoever -- fearing that the companies are putting profits above safety -- all generic-drug companies will be hurt.
The Motley Fool January 27, 2005 Rich Duprey	Profits Sail at Digital River E-commerce outsourcer posts record profits and earnings.
The Motley Fool September 5, 2006 Tom Taulli	Wind River Flying High With Linux After a fairly strong quarter, will the wind keep blowing forward for the software developer and its shareholders?
The Motley Fool September 9, 2008 Brian Orelli	Sell Dey? Perhaps Another Day Generic-drug company Mylan decides to keep its specialty pharmaceutical subsidiary.
The Motley Fool October 12, 2009 Rich Duprey	How to Lose 30% in One Day Digital River lost 30% of its revenue in one day when Internet security provider Symantec decided it could provide the same e-commerce services it currently outsources to Digital River, and announced that it won't extend the contract between the two companies.
The Motley Fool February 7, 2007 Brian Lawler	Mylan Adjusts to the Matrix The drugmaker got a bump from a new generic and settles in with its Matrix acquisition. Investors, take note.
The Motley Fool October 31, 2008 Brian Orelli	A Generic McMansion Mylan took an awfully big bite when it purchased Merck KGaA's generic-drug business last year, but so far it's proven that it can handle it.
The Motley Fool April 30, 2009 Brian Orelli	A Great Generic Recovery After getting punished for taking on an acquisition, Mylan is doing pretty well.